The role of T cell interleukin-17 in conducting destructive arthritis: Lessons from animal models

Arthritis Research and Therapy

Volumn 7, Issue 1, 2005, Pages 29-37

  Lubberts, Erik ^a   Koenders, Marije ^a   van den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Autoimmune diseases; Cytokine; Inflammation; Interleukin 23; Osteoclast; Receptor activator of NF B ligand

Indexed keywords

ADENOVIRUS VECTOR; ANTIRHEUMATIC AGENT; CD4 ANTIGEN; CD45RO ANTIGEN; CYTOKINE ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 25; INTERLEUKIN 27; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOCLAST DIFFERENTIATION FACTOR; STROMELYSIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

AUTOIMMUNE DISEASE; BONE EROSION; CARTILAGE DEGENERATION; CELL TRANSPORT; CELLULAR IMMUNITY; CORRELATION FUNCTION; CYTOKINE PRODUCTION; DISEASE MODEL; GENE OVEREXPRESSION; HUMAN; IN VIVO STUDY; INFLAMMATION; JOINT DESTRUCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PATHOGENESIS; POLYMORPHONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIAL FLUID; T LYMPHOCYTE; VIRAL GENE THERAPY;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BONE AND BONES; CARRIER PROTEINS; CARTILAGE, ARTICULAR; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-17; INTERLEUKINS; MEMBRANE GLYCOPROTEINS; MICE; NEUTROPHILS; OSTEOCLASTS; RANK LIGAND; RATS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-17; SPECIES SPECIFICITY; SYNOVIAL FLUID; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 13444256307     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1478     Document Type: Review

References (80)

1. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin J-J, Garrone P, Garcia E, Saeland S, et al.: T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603.
2. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, Armitage RJ: Human IL-17: a novel cytokine derived from T cells. J Immunol 1995, 155:5483-5486.
3. - T cells. J Interferon Cytokine Res 1996, 16:611-617.
4. Rouvier E, Luciani M-F, Mattei M-G, Denizot F, Golstein P: CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a Herpesvirus Saimiri gene. J Immunol 1993, 150:5445-5456.
5. Yao Z, Fanslow WC, Seldin MF, Rousseau A-M, Painter SL, Comeau MR, Cohen JI, Spriggs MK: Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995, 3:811-821.
6. Aggarwal S, Gurney AL: IL-17: prototype member of an emerging cytokine family. J Leuk Biol 2002, 71:1-8.
7. Li H, Chen J, Huang A, Stinson J, Heldens S, Foster J, Dowd P, Gurney AL, Wood WI: Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. Proc Natl Acad Sci USA 2000, 97:773-778.
8. Shi Y, Ullrich SJ, Zhang J, Connolly K, Grzegorzewski KJ, Barber MC, Wang W, Wathen K, Hodge V, Fisher CL, et al.: A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem 2000, 275:19167-19176.
9. Lee J, Ho WH, Maruoka M, Corpuz RT, Baldwin DT, Foster JS, Goddard AD, Yansura DG, Vandlen RL, Wood WI, et al.: IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol Chem 2001, 276:1660-1664.
10. Starnes T, Robertson MJ, Sledge G, Kelich S, Nakshatri H, Broxmeyer HE, Hromas R: Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol 2001, 167:4137-4140.
11. Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P, Maruoka M, Mao W, Foster J, Kelley RF, et al.: IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J 2001, 20: 332-5341.
12. Schwandner R, Yamaguchi K, Cao Z: Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin-17 signal transduction. J Exp Med 2000, 191:1233-1240.
13. Awane M, Andres PG, Li DJ, Reinecker HC: NF-κB-inducing kinase is a common mediator of IL-17-, TNF-α and IL-1β-induced chemokine promoter activation in intestinal epithelial cells. J Immunol 1999, 162:5337-5344.
14. Shalom-Barak T, Quach J, Lotz M: Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB. J Biol Chem 1998, 273:27467-27473.
15. Laan M, Lotvall J, Chung KF, Linden A: IL-17-induced cytokine release in human bronchial epithelial cells in vitro: role of mitogen-activated protein (MAP) kinases. Br J Pharmacol 2001, 133:200-206.
16. Kehlen A, Thiele K, Riemann D, Langner J: Expression, modulation and signaling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin Exp Immunol 2002, 127:539-546.
17. Haudenschild D, Moseley T, Rose L, Reddi AH: Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer. J Biol Chem 2002, 277:4309-4316.
18. Moseley TA, Haudenschild DR, Rose L, Reddi AH: Interleukin-17 family and IL-17 receptors. Cytokine & Growth Factor Reviews 2003, 14:155-174.
19. Infante-Duarte C, Horton HF, Byrne MC, Kamradt T: Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 2000, 165:6107-6115.
20. Thiele K, Riemann D, Navarrete Santos A, Langner J, Kehlen A: Cell-cell contact of human T cells with fibroblasts changes lymphocytic mRNA expression: increased mRNA expression of interleukin-17 and interleukin-17 receptor. Eur Cytokine Netw 2000, 11: 3-58.
21. Ziolkowska M, Koc A, Luszczykiewics G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, Maslinski W: High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000, 164:2832-2838.
22. Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A: IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 2003, 170:2106-2112.
23. Aggarwal S, Gilardi N, Xie MH, de Sauvage FJ, Gurney AL: Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003, 17:1910-1914.
24. Happel KI, Zheng M, Young E, Quinton LJ, Lockhart E, Ramsay AJ, Shellito JE, Schurr JR, Bagby GJ, Nelson S, et al.: Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J Immunol 2003, 170:4432-4436.
25. Cua DJ, Sherlock J, Chen YI, Murphy CA, Joyce B, Seymour B, Luclan L, To W, Kwan S, Churakova T, et al.: Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 42:744-748.
26. Murphy C, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedwick JD, Cua DJ: Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957.
27. Ghilardi N, Kljavin N, Chen Qi, Lucas S, Gurney AL, de Sauvage FJ: Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J Immunol 2004, 172: 2827-2833.
28. Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I, Sekikawa K, Asano M, Iwakura Y: Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002, 17:375-387.
29. Miossec P: Interleukin-17 in rheumatoid arthritis. If T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 2003, 48:594-601.
30. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P: Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999, 42:963-970.
31. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, et al.: IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103: 1345-1352.
32. Aarvak T, Chabaud M, Miossec P, Natvig JB: IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999, 162:1246-1251.
33. Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G: Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-γ and interleukin-4 induced activation of human keratinocytes. J Invest Dermatol 2000, 115:81-87.
34. Jovanovic DV, DiBattista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, Mineau F, Pelletier J-P: IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNFα, by human macrophages. J Immunol 1998, 160:3513-3521.
35. Chabaud M, Fossiez F, Taupin JL, Miossec P: Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998, 161:409-414.
36. Katz Y, Nadiv O, Beer Y: Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukin 1, 6, and 8 in skin and synovial fibroblasts: a possible role as a 'fine-tuning cytokine' in inflammation processes. Arthritis Rheum 2001, 44: 2176-2184.
37. Chabaud M, Miossec P: The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum 2001, 44:1293-1303.
38. Lubberts E: The role of IL-17 and family members in the pathogenesis of arthritis. Curr Opin Investig Drugs 2003, 4: 72-577.
39. Nakae S, Nambu A, Sudo K, Iwakura Y: Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003, 171:6173-6177.
40. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y: IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003, 100:5986-5990.
41. Lubberts E, Joosten LAB, Oppers B, Van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, Schwarzenberger P, Van de Loo FA, Van den Berg WB: IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001, 167:1004-1013.
42. Lubberts E, Koenders MI, Oppers-Walgreen B, Van den Bersselaar L, Coenen-de Roo CJJ, Joosten LAB, Van den Berg WB: Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004, 50:650-659.
43. Lubberts E, Joosten LAB, Van de Loo FA, Schwarzenberger P, Kolls JK, Van den Berg WB: Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res 2002, 51: 02-104.
44. Chabaud M, Lubberts E, Joosten L, Van den Berg W, Miossec P: IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001, 3:168-177.
45. Lubberts E, Joosten LAB, Van de Loo FAJ, Van den Bersselaar L, Van den Berg WB: Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4. Arthritis Rheum 2000, 43: 1300-1306.
46. Dudler J, Renggli-Zulliger N, Busso N, Lotz M, So A: Effect of interleukin-17 on proteoglycan degradation in murine knee joints. Ann Rheum Dis 2000, 59:529-532.
47. Cai L, Yin JP, Starovasnik MA, Hogue DA, Hillan KJ, Mort JS, Filvaroff EH: Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. Cytokine 2001, 16: 0-21.
48. Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P: Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 2000, 12:1092-1099.
49. Benderdour M, Tardif G, Pelletier JP, Di Battista JA, Reboul P, Ranger P, Martel-Pelletier J: Interleukin 17 (IL-17) induces collagenase-3 production in human osteoclastic chondrocytes via AP-1 dependent activation: differential activation of AP-1 members by IL-17 and IL-1β. J Rheum 2002, 29:1262-1272.
50. Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD: Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002, 61:704-713.
51. Van den Berg WB: Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 2001, 3:18-26.
52. Attur MG, Patel RN, Abramson SB, Amin AR: Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage. Arthritis Rheum 1997, 40:1050-1053.
53. Martel-Pelletier J, Mineau F, Jovanovic D, Di Battista JA, Pelletier JP: Mitogen-activated protein kinase and nuclear factor κB together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes: possible role of transactivating factor mitogen-activated protein kinase-activated protein kinase (MAPKAPK). Arthritis Rheum 1999, 42: 2399-2409.
54. 2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum 2001, 44:2078-2083.
55. Van Bezooijen RL, Van der Wee-Pals L, Papapoulos SE, Lowik CW: Interleukin 17 synergizes with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis 2002, 61:870-876.
56. Schalkwijk J, Van den Berg WB, Joosten LAB, Van den Putte LBA: Elastase secreted by activated polymorphonuclear leukocytes causes chondrocyte damage and matrix degradation in intact articular cartilage: escape from inactivation by alpha-1-proteinase inhibitor. Br J Exp Pathol 1987, 68:81-88.
57. Campbell EJ, Silverman EK, Campbell MA: Elastase and cathepsin G of human monocytes: quantification of cellular content, release in response to stimuli, and heterogeneity in elastase-mediated proteolytic activity. J Immunol 1989, 143:2961-2968.
58. Bezooijen R, Farih-Sips HC, Papapoulos SE, Lowik CW: Interleukin-17: a new bone acting cytokine in vitro. J Bone Min Res 1999, 14:1513-1521.
59. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, et al.: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
60. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, et al.: RANK is essential for ostoclast and lymph node development. Genes Dev 1999, 13:2412-2424.
61. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HO, Wooden S, Bennett L, Boone T, et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
62. Lubberts E, Joosten LAB, Chabaud M, Van den Bersselaar L, Oppers B, Coenen-de Roo CJJ, Richards CD, Miossec P, Van den Berg WB: IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000, 105:1697-1710.
63. Bush KA, Farmer KM, Walker JS, Kirkham BW: Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 2002, 46:802-805.
64. Lubberts E, Van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJJ, Kolls JK, Joosten LAB, Van den Berg WB: IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the RANKL/OPG balance. J Immunol 2003, 170: 655-2662.
65. Laan M, Cui ZH, Hoshino H, Lotvall J, Sjostrand M, Gruenert DC, Skoogh BE, Linden A: Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999, 162: 347-2352.
66. Hurst SD, Muchamuel T, Gorman DM, Gilbert JM, Clifford T, Kwan S, Menon S, Seymour B, Jackson C, Kung TT, et al.: New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Immunol 2002, 169: 443-453.
67. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y: Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003, 52:65-70.
68. Katz Y, Nadiv O, Beer Y: Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukin 1, 6, and 8 in skin and synovial fibroblasts: a possible role as a 'fine-tuning cytokine' in inflammation processes. Arthritis Rheum 2001, 44: 2176-2184.
69. Toda M, Leung DY, Molet S, Boguniewicz M, Taha R, Christodoulopoulos P, Fukuda T, Elias JA, Hamid QA: Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol 2003, 111:75-81.
70. Katz Y, Nadiv O, Rapoport MJ, Loos M: IL-17 regulates gene expression and protein synthesis of the complement system, C3 and factor B, in skin fibroblasts. Clin Exp Immunol 2000, 120:22-29.
71. Schwarzenberger P, La Russa V, Miller A, Ye P, Huang W, Zieske A, Nelson S, Bagby GJ, Stoltz D, Mynatt RL, et al.: IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol 1998, 161:6383-6389.
72. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara. H, Lotze MT: Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003, 101:2620-2627.
73. Antonysamy MA, Fanslow WC, Fu F, Li W, Qian S, Troutt AB, Thomson AW: Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 1999, 162: 577-584.
74. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang P, Zhang J, et al.: Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defence. J Exp Med 2001, 194: 19-527.
75. Pan G, French D, Mao W, Maruoka M, Risser P, Lee J, Foster J, Aggarwal S, Nicholes K, Guillet S, et al.: Forced expression of murine IL-17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan inflammation in mice. J Immunol 2001, 167:6559-6567.
76. Kato T, Furumoto H, Ogura T, Onishi Y, Irahara M, Yamano S, Kamada M, Aono T: Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun 2001, 282:735-738.
77. Tartour E, Fossiez F, Joyeux L, Galinha A, Gey A, Claret E, Sastre-Garau X, Couturier J, Mosseri V, Vives V, et al.: Interleukin-17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999, 59: 698-3604.
78. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, et al.: Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002, 8: 00-508.
79. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, Takabayashi K, Iwamoto I: Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000, 43: 2455-2463.
80. Starnes T, Broxmeyer HE, Robertson MJ, Hromas R: Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol 2002, 169: 42-646.